SEARCH · PubMed Health

Results for “TOXOPLASMOSIS, CONGENITAL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,171 records · Page 65Linked to original sources

PubMed1988

[Prenatal toxoplasmosis: diagnosis and prevention].

Sera of six children, clinically suspected of having congenital toxoplasmosis, and of their mothers were examined for specific antibodies. In four, prenatal infection was established shortly after birth by significant titre differences between the neonatal and maternal sera. In three neonates, toxoplasma-specific IgM antibodies were demonstrated. In two children, aged seven and 16 months, postnatal infection could not be absolutely excluded, although both they and their mothers had high toxoplasma antibody titres.

Animals↗

PubMed2003

Fetal toxoplasmosis and negative amniocentesis: necessity of an ultrasound follow-up.

Prenatal diagnosis of congenital toxoplasmosis relies on the PCR test on amniotic fluid and ultrasound follow-up of the fetus. We report two cases of toxoplasma infection during the first trimester of gestation with a discrepant diagnosis of fetal infection. PCR performed more than four weeks after the estimated date of contamination was negative. Ultrasound follow-up was normal up to the third trimester when major hydrocephalus was detected, leading to pregnancy termination. In both cases, post-mortem examination revealed a diffuse infection with severe brain lesions. These observations confirm the necessity to continue a monthly ultrasound follow-up, even if amniocentesis is negative, in case of fetal toxoplasma infection in pregnancy.

Abortion, Induced↗

PubMed1992

No interference of rheumatoid factor(s) with toxoplasmosis IgM determination in infancy.

Sera from 263 newborns and infants suspected of congenital toxoplasmosis were tested for the presence of rheumatoid factor (RF) by the latex agglutination test, of which 40 were also tested by the enzyme-linked immunosorbent assay (ELISA). RF was detected in only one serum sample (0.38%), suggesting that false-positive results of the IgM-indirect fluorescent antibody test and the IgM-ELISA due to RF is most unusual in infancy.

Enzyme-Linked Immunosorbent Assay↗

PubMed2004

Prevention of toxoplasmosis during pregnancy--an epidemiologic survey over 22 consecutive years.

BACKGROUND: Prevention of congenital toxoplasmosis is most often based on the results of a serological screening program in pregnant women followed by prenatal and postnatal treatment of women and their newborns when infection is already established during pregnancy or on cord blood (secondary prevention). Little effort has been made to study primary prevention of toxoplasmosis during pregnancy. OBJECTIVE: To assess the possibilities of two different programs aimed at preventing the acquisition of toxoplasmosis during pregnancy. METHODS: During the first study period (1979-1982) the natural incidence of toxoplasmosis in pregnancy was studied in 2986 pregnant women. In the second study period (1983-1990) the incidence of toxoplasmosis was studied in 8300 women. During this period, seronegative women received a written list of recommendations on how to avoid a toxoplasma infection during pregnancy. In the third study period (1991-2001) the incidence of toxoplasmosis was studied in 16,541 women. During this period, the prevention campaign consisted of a leaflet explaining a) toxoplasmosis as a disease and b) what measures should be taken to avoid toxoplasmosis during pregnancy. The third part of the campaign involved a reiteration of these recommendations during antenatal classes held around mid-gestation. The impact of the two prevention programs was studied by measuring the seroconversion rate in seronegative women. RESULTS: Twenty of 1403 seronegative women in the first period (1.43%), 19 of 3605 women in the second period (0.53%) and 8 of 8492 in the third period (0.09%) seroconverted during pregnancy. The first prevention campaign reduced the seroconversion rate by 63% (p<0.05 OR 2.729 95% CI 1.452-5.084). The second prevention program resulted in a reduction rate of 92% compared to the seroconversion rate in the first period (p<0.0001 OR 15.34 95% CI 6.741-34.89). CONCLUSION: Promotion of simple measures is very effective in the prevention of toxoplasmosis during pregnancy. Primary prevention should not only be based on education about preventive measures given by physicians, but these guidelines should be reiterated during antenatal classes and leaflets distributed containing written recommendations on the nature of the disease and its avoidance.

Belgium↗

PubMed1990

[Should immunologic monitoring of toxoplasmosis seronegative pregnant women stop at delivery?].

The authors report 2 cases of congenital toxoplasmosis fortuitously diagnosed in 2 newborn infants aged 12 and 35 days respectively whose mothers had no anti-Toxoplasma antibodies detectable at the time of birth. These cases prompted us to carry out, over an 18 months' period, a systematic postnatal control of all pregnant women who were still seronegative at the time of delivery. This enabled us to detect 4 cases of perinatal maternal infection with Toxoplasma contamination in 2 neonates. In view of these results, and in order not to miss any maternal infection at the very end of pregnancy, it seems advisable to complete the control of seronegative women by taking a last blood sample about 30 days after they have given birth.

Adult↗

PubMed1993

[Antenatal diagnosis of toxoplasmosis. 176 case reports].

OBJECTIVE: To determine the value of antenatal diagnosis of congenital toxoplasmosis by ultrasound guided aspiration of cord blood for testing. MATERIAL: This is a prospective study of 176 cases. As well as obtaining fetal blood and amniotic fluid the searched for specific IgM and A as well as culturing for the parasites on human fibroblasts and inoculation of mice, as well as researching them for non-specific signs of fetal infection. 149 children were able to be followed up one year after birth. RESULTS: 15% of the children (22/149) were infected with toxoplasmosis. 11 out of these were diagnosed positive antenatally. For the 11 others the diagnosis of fetal infection could only be made after birth, but the non-specific signs made it possible to expect early that they had been contaminated. 59% (13/22) had latent toxoplasmosis which only showed up after a mean interval of 34 months after birth. 41% (9/22) had clinical and/or paraclinical signs of toxoplasmosis (mainly unilateral non-macular chorioretinitis and intracranial calcifications) but they are well after a follow-up period averaging 30 months. COMMENTARY: Ultrasound alone, when it shows up fetal abnormalities, can make the diagnosis of the severity of the condition. The role of taking fetal specimens is to make clear those infants that are infected because of specific signs, and to find those fetuses which are at high risk because of non-specific signs in order to improve the management of the cases. This development has made it possible to avoid carrying out a large number of unnecessary terminations of pregnancy and has resulted in the birth of affected infants that had no functional sequelae from the infection.

Amniotic Fluid↗

PubMed1975

Toxoplasmosis. Historical review, direct diagnostic microscopy, and report of a case.

A case of congenital toxoplasmosis diagnosed by the detection of Toxoplasma gondii organisms in the ventricular fluid of a living patient, confirmed by mouse inoculation, is reported. The subject of toxoplasmosis is reviewed historically, especially in regard to cases diagnosed by direct microscopic examination of cerebrospinal or ventricular fluids. Although several such cases have been reported in the world medical literature, an extensive survey failed to reveal such a case previously reported in the United States.

Brain↗

PubMed1993

Immunoglobulin-A detection and the investigation of clinical toxoplasmosis.

Current serological methods for the investigation of Toxoplasma gondii infection are unreliable for the diagnosis of congenital disease, reactivated infection associated with the acquired immune deficiency syndrome (AIDS), or the determination of the date of onset of infection. An enzyme-linked immunosorbent assay (ELISA) and an immunosorbent agglutination assay (ISAGA) were developed for the detection of toxoplasma-specific immunoglobulin-A (IgA) and used to investigate patients in these three categories. The IgA ISAGA and IgA ELISA were found to be reproducible and specific tests. The IgA ISAGA demonstrated enhanced sensitivity. Measurement of IgA in patients with toxoplasma-associated lymphadenopathy of known duration and AIDS patients with toxoplasma infection was of limited value. Detection of specific IgA by ISAGA was more sensitive than conventional methods for the diagnosis of congenital toxoplasmosis. We recommend the investigation of infant sera with IgA ISAGA. IgA estimation is not indicated in other clinical situations.

Acquired Immunodeficiency Syndrome↗

PubMed1970

Toxoplasmosis of the central nervous system in children.

The clinical symptoms and signs of 17 children with congenital toxoplasmosis of the brain are reported. Moreover the neuropathological lesions of 8 cases were given. The clinical findings of 10 children with acquired toxoplasmosis were tabulated. Problems concerning the diagnosis and differential diagnosis of toxoplasmosis of the central nervous system were discussed.

Brain↗

PubMed1994

Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group.

BACKGROUND: Most infants with congenital Toxoplasma gondii infection have no symptoms at birth, but many will have retinal disease or neurologic abnormalities later in life. Early detection and treatment of congenital toxoplasmosis may reduce these sequelae. METHODS: In Massachusetts since January 1986, and in New Hampshire since July 1988, newborns have been screened for intrauterine infection with T. gondii by means of an IgM capture immunoassay of blood specimens routinely collected for screening for metabolic disorders. Congenital infection is confirmed by assays for specific IgG and IgM antibodies in serum from infants and their mothers. For this study, infants with serologic evidence of infection underwent extensive clinical evaluation and received one year of treatment. RESULTS: Through June 1992, 100 of 635,000 infants tested had positive screening tests. Congenital infection was confirmed in 52 infants, 50 of whom were identified only through neonatal screening and not through initial clinical examination. However, after the serologic results became available, more detailed examinations revealed abnormalities of either the central nervous system or the retina in 19 of 48 infants evaluated (40 percent). After treatment, only 1 of 46 children had a neurologic deficit (hemiplegia attributable to a cerebral lesion present at birth). Thirty-nine treated children had follow-up ophthalmologic examinations when one to six years old; four (10 percent) had eye lesions that may have developed postnatally (a macular lesion in one child and minor retinal scars in three). CONCLUSIONS: Routine neonatal screening for toxoplasmosis identifies congenital infections that are subclinical, and early treatment may reduce the severe long-term sequelae.

Antibodies, Protozoan↗

PubMed1999

Recurrent ocular disease in postnatally acquired toxoplasmosis.

PURPOSE: Although recurrences are typical of congenital toxoplasmosis, the long-term ocular manifestations in postnatally acquired toxoplasmosis have never been systematically studied. We report on the ocular manifestations complicating the chronic phase of postnatally acquired toxoplasmosis. METHODS: Review of the clinical data of 14 patients who presented with active ocular toxoplasmosis not associated with scars and who had serologic characteristics of recently acquired systemic toxoplasmosis. RESULTS: Mean follow-up was 4.6 years. Recurrent ocular disease developed in eight (57%) of 14 cases. The number of patients with recurrences increased with the follow-up time: four (29%) of 14 during the first year of follow-up; eight (57%) of 14 during the second year; and eight of nine during the third follow-up year. No risk factors for the development of recurrences were identified. Satellite lesions developed in five of eight patients with recurrences, whereas lesions not adjacent to old scars, located in areas of previously unaffected retina, developed in three patients. CONCLUSIONS: In postnatally acquired toxoplasmosis, frequent recurrences of ocular disease can be seen during the chronic phase of infection.

Adolescent↗

PubMed1992

Treatment of toxoplasmosis in the pregnant mother and newborn child.

The paper presents a review of different treatment regimens employed for 25 years to prevent and treat congenital toxoplasmosis. Unfortunately, no well-controlled, randomized trials have been performed to evaluate the efficacy of different therapies of pregnant women or infected neonates. Treatment in pregnancy may be effective since transplacental passage of parasites is delayed. Spiramycin, a complete safe drug which concentrates in the placenta, may reduce the risk of materno-fetal transmission by 60%, but is in the present doses without influence on an already infected fetus. Pyrimethamine in combination with sulfonamides erradicates more effectively parasites in the placenta, and also in the fetus. Today a combination of both regimens is recommended in pregnancy. As for the infected neonates, intensive treatment of pyrimethamine/sulfonamides alternating with spiramycin until one year of age seems to prevent development of late appearing sequelae. There is obviously a need for international multicenter studies to settle the optimal schedules and duration of therapy which again is highly dependent on the performance of an appropriate serological screening during pregnancy.

Abortion, Therapeutic↗

PubMed2004

[Maternal toxoplasmosis before conception and chorioretinitis in twin sisters].

A maternal toxoplasmosis before conception is exceptionally transmitted to the fetus. We report an observation of twin sisters who presented congenital toxoplasmosis with chorioretinitis detected at nine months of age. The anamnesis revealed that the mother had had toxoplasmosis one month before conception. In the event of preconceptual infections, we propose fetal ultrasonography, histological examination of the placenta at delivery, as well as a pediatric follow-up of the infants (serological samples every month, cranial ultrasonography, fundus oculi).

Adult↗

PubMedDate not supplied

[Toxoplasmosis serodiagnosis: comparison of Access Toxo IgM II assay compared to Axsym Toxo IgM and Vidas Toxo IgM assays].

The Access Toxo IgM II test (Beckman Coulter Inc) was evaluated on 1,190 samples from toxoplasmosis serology requests, documented seroconversions, umbilical cord blood or venous blood from healthy newborn, and from newborns with congenital toxoplasmosis. Results were compared to those obtained with Vidas (bioMérieux) and Axsym (Abbott) assays, with Isaga as confirmatory technique. Results obtained with the Access test well correlate those with the Vidas (98.3%) and the Axsym (97.6%) assays. Less "bordeline" results are also observed with the Access test (0.22% versus 0.56% and 1.24% with Vidas and Axsym assays respectively). Results obtained from seroconverted patients prove that the Access assay is more sensitive than Vidas and Axsym assays, with respectively 2 and 4 samples detected earlier for 28 cases studied (recently seroconverted patients). Results obtained using prospective samples and with sequential sera obtained from patients with seroconversion clearly demonstrate that Access Toxo IgM II assay is perfectly adapted to toxoplasmosis diagnosis.

Adult↗

PubMed2002

Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid.

Toxoplasma infection during pregnancy is widely treated with oral spiramycin to reduce the risk of congenital toxoplasmosis in the infant. Failures of therapy have been observed, however. In this study, a sensitive high-performance liquid chromatography technique was used to measure concentrations of spiramycin and neospiramycin, one of the major metabolites of spiramycin, in maternal serum and amniotic fluid. Samples were obtained from 18 women who underwent amniocentesis for polymerase chain reaction (PCR) diagnosis of fetal infection 5-109 days following the prescription of spiramycin therapy (3 g/day). Concentrations of spiramycin and neospiramycin in both serum and amniotic fluid were highly variable, ranging from nondetectable values to 1 microg/ml. None of the concentrations measured were within the range reported to inhibit growth of the parasite in vitro. Consistent with previous reports, part of the observed variability in maternal and fetal drug concentrations could be explained by individual differences in several pharmacokinetic parameters: intestinal absorption, tissue distribution, cellular uptake, metabolism, transfer across the placenta, drug accumulation in fetal tissue, and maternal and fetal drug elimination. The heterogeneity of the data could also be related to differences in patient compliance with the medication prescribed. By addressing factors that could impair adequate treatment of toxoplasmosis during pregnancy, the data presented call for a larger-scale controlled study to determine individual and diurnal variations in maternal drug levels, patient compliance, and outcomes of the offspring. The activity of neospiramycin against Toxoplasma gondii should be assessed.

Adolescent↗

PubMed1986

[Follow-up of children after toxoplasmosis infection in pregnancy].

A vival toxoplasmosis infection was diagnosed in 188 cases (3,8%) out, of 49,582 pregnant women routinely screened. 4 children live with congenital toxoplasmosis. Follow-up studies showed that 33 children have specific antibodies, 5 are with suspect clinical findings. Therefore is the conclusion that more late signs of connatal toxoplasmosis are to be detected by follow-up investigations.

Antibodies↗

PubMedDate not supplied

[Screening for toxoplasmosis in pregnancy: more harm than good].

Using data from international literature makes it possible to calculate for Germany benefit and harm of a screening for toxoplasmosis in pregnancy. On the basis of these data harm of such a screening is much greater than benefit. Taking the reported number of congenital toxoplasmosis in Germany as the base for such a calculation of harm and benefit makes the ratio of benefit and harm even worse.

Abortion, Induced↗

PubMed1991

Pattern of antibodies in toxoplasmosis of pregnant women and their children in Thailand.

The latex agglutination test for toxoplasmosis was performed on 690 blood samples collected from the Veterans and Bang Bua Thong Hospitals in Bangkok. Blood samples were collected in the first- and the third-trimester from pregnant women and from the cord blood. The seroprevalence of toxoplasmosis in the first trimester was 13.14%, 13.60%; in the third trimester was 12.21%, 9.43% and in the cord blood 7.18% and 13.04% for the Veterans Hospital and Bang Bua Thong Hospital, respectively. There was no significant difference between the prevalence of toxoplasmosis for each type of blood from both hospitals. The average prevalence of toxoplasmosis for Thai pregnant women in the first- and third-trimester was 13.38% and 11.41%, respectively, and that for the cord blood was 9.01%. Congenital toxoplasmosis occurred in children of untreated mothers who were seropositive or seronegative in the third-trimester, the infection rates of the fetus being 46.67% and 8.13% respectively.

Animals↗